CEL-SCI Corporation
8229 Boone Boulevard
Suite 802
Vienna
VA
22182
United States
Tel: (703) 506-9460
Website: http://www.cel-sci.com/
About CEL-SCI Corporation
CEL-SCI Corporation is a pioneer in cancer immunotherapy. We are a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer, infectious and autoimmune diseases. CEL-SCI believes that boosting a patient's immune system before surgery, radiation and chemotherapy should provide the greatest possible impact on survival since that is the time when the immune system is the strongest. Therefore, in the Phase 3 clinical study CEL-SCI treated patients who were newly diagnosed with head and neck cancer with Multikine immunotherapy right after diagnosis, BEFORE they went on to receive surgery, radiation and/or chemotherapy. This approach is unique since cancer drugs are mostly given after surgery, radiation and chemotherapy have failed. The Phase 3 study is the largest ever in head and neck cancer with 928 patients enrolled. It reached the targeted threshold required to conduct data evaluation and is currently in the statistical analysis phase. Head and neck cancer represents about 6% of all cancers worldwide and an unmet medical need. Multikine has received Orphan Drug designation from the FDA for this indication. CEL-SCI operates its own 73,000 sq. ft. GMP manufacturing facility that produces Multikine and a separate research & development laboratory that supports the manufacturing of Multikine. CEL-SCI has operations in Vienna, Virginia, and near/in Baltimore, Maryland.
Stock Symbol: CVM
CEL-SCI Corporation Overview
468 articles with CEL-SCI Corporation
-
CEL-SCI Announces 2007 Financial Results
1/14/2008
-
CEL-SCI Announces Adoption of Shareholder Rights Plan
11/12/2007
-
Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
10/29/2007
-
CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9/19/2007
-
CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
9/18/2007
-
CEL-SCI Releases Letter to Shareholders
9/10/2007
-
CEL-SCI to Present at the Noble Financial Conference
8/20/2007
-
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug, More Jobs
8/14/2007
-
CEL-SCI Reports Third Quarter 2007 Financial Results
8/14/2007
-
CEL-SCI Releases Letter to Shareholders
6/13/2007
-
CEL-SCI CEO to Present at Dutton Associates' 'Recognizing Opportunity' SmallCap Conference in San Francisco May 30
5/29/2007
-
CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5/23/2007
-
CEL-SCI Presents Long-Term Cancer Survival Data With Multikine(R)
5/21/2007
-
CEL-SCI Reports Second Quarter 2007 Financial Results
5/15/2007
-
CEL-SCI to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference
5/14/2007
-
CEL-SCI to Present at Biotechnology Industry Organization (BIO) 2007 Business Forum
5/7/2007
-
CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
5/1/2007
-
CEL-SCI Announces Issuance of U.S. Patent for New Platform Technology to Treat Immune System-Based Diseases
4/26/2007
-
CEL-SCI Announces Important Publication by Two of its Key Scientists
4/24/2007
-
CEL-SCI Announces $15 Million Financing
4/18/2007